Jazz Pharmaceuticals (US.JAZZ)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.JAZZ · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 95.2% | → |
| ROE | 6.5% | ↑ |
| Cash Conversion | 139.3% | → |
| D/E Ratio | 1.20 | ↑ |
| Gross Margin | 87.5% | → |
US.JAZZ (Jazz Pharmaceuticals) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 95.2% → ROE 6.5% ↑ Cash Conversion 139.3% → D/E Ratio 1.20 ↑ Gross Margin 87.5% →
Key Metrics
US.JAZZ (Jazz Pharmaceuticals) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 95.2% →ROE 6.5% ↑Cash Conversion 139.3% →D/E Ratio 1.20 ↑Gross Margin 87.5% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies